These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 34527619)

  • 1. Complete Response to Afatinib of an EGFR Exon 18 delE709_T710insD-Mutated Stage IV Lung Adenocarcinoma.
    Jelli B; Taton O; D'Haene N; Remmelink M; Mekinda Z
    Eur J Case Rep Intern Med; 2021; 8(8):002749. PubMed ID: 34527619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
    Ibrahim U; Saqib A; Atallah JP
    Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.
    An N; Wang H; Zhu H; Yan W; Jing W; Kong L; Zhang Y; Yu J
    Onco Targets Ther; 2019; 12():7399-7404. PubMed ID: 31686847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
    Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR exon 18 delE709_T710insD mutated stage IV non-small cell lung cancer treated with osimertinib: a case report.
    Valcárcel S; Villanueva N; Álvarez C; Esteban E
    Anticancer Drugs; 2024 Aug; 35(7):638-640. PubMed ID: 38513159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.
    Kobayashi Y; Togashi Y; Yatabe Y; Mizuuchi H; Jangchul P; Kondo C; Shimoji M; Sato K; Suda K; Tomizawa K; Takemoto T; Hida T; Nishio K; Mitsudomi T
    Clin Cancer Res; 2015 Dec; 21(23):5305-13. PubMed ID: 26206867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to dacomitinib in advanced non-small-cell lung cancer harboring the rare delE709_T710insD mutation: A case report.
    Xu F; Xia ML; Pan HY; Pan JW; Shen YH
    World J Clin Cases; 2022 Jun; 10(17):5916-5922. PubMed ID: 35979118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR exon 18 DelE709_T710insD as an Acquired Resistance Mechanism to Afatinib in an Advanced EGFR exon 18 E709H Lung Adenocarcinoma.
    Zeng L; Zhang Y; Yang N
    J Thorac Oncol; 2018 Jun; 13(6):e93-e95. PubMed ID: 29793651
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer.
    Wu JY; Shih JY
    Onco Targets Ther; 2016; 9():6137-6145. PubMed ID: 27785061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.
    Liang SK; Ko JC; Yang JC; Shih JY
    Lung Cancer; 2019 Jul; 133():103-109. PubMed ID: 31200815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis.
    Rubiera-Pebe R; Hicks JK; Tanvetyanon T
    Cancer Treat Res Commun; 2021; 28():100407. PubMed ID: 34090219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung Adenocarcinoma Patient Harboring
    Zhao L; Wang Z; Du H; Chen S; Wang P
    Front Oncol; 2021; 11():605853. PubMed ID: 33898306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
    van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
    J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare
    Zöchbauer-Müller S; Kaserer B; Prosch H; Cseh A; Solca F; Bauer MJ; Müllauer L
    Front Oncol; 2020; 10():593852. PubMed ID: 33575211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
    Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
    Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report.
    Wu L; Fang C; Zhao W; Li D; Tang S; Li X; Ji M
    Ann Transl Med; 2022 Jan; 10(2):116. PubMed ID: 35282062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report.
    Long X; Qin T; Lin J
    Onco Targets Ther; 2020; 13():10689-10692. PubMed ID: 33116645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.